Group	Cluster	Identifiers
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	0	M6PR	ERH	EEF1D	SRSF7	TCP1	TPT1	C7orf50	RPL4	RPL14	HMGN1
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	1	PSMB1	BLZF1
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	2	CDK13	ARHGEF1	RPL18A	PDPK1	EIF3M	RPL26	SF1	NAA20	RPS17
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	3	U2AF1	RBM12B
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	4	LRPPRC	FAM72B
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	5	ARID4B	CAMKK2	NCK1	SAMD4B
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	6	DDX17	PNPT1
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	7	ZBTB40
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	8	PTPRC	NFAT5	PCYOX1	CCDC93	UGP2
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	9
QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE	10	RAB27A	NT5C3A
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	0
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	1
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	2
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	3	ACTB	PLEKHB2	GRB2	ARPC4
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	4
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	5
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	6
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	7	ARRB1
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	8
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	9
HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP	10
